Tech Company Financing Transactions
Sesen Bio Funding Round
Flagship Pioneering, Rally Ventures and Third Rock Ventures participated in a $20 million Series A funding round for Sesen Bio. The round was announced on 5/8/2012.
Transaction Overview
Company Name
Announced On
5/8/2012
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance Eleven's first program, EBI-005, into clinical development while continuing to advance earlier stage programs generated by its proprietary AMP-Rx product engine.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 First St. 1800
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Sesen Bio (formerly Eleven Biotherapeutics) is focused on developing innovative protein-based therapeutics to improve human health and treat diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen Hurly
Chief Financial Officer
Richard Fitzgerald
Chief Scientific Officer
Gregory Adams
Chief Technical Officer
Glen MacDonald
Vice President
David Brooks
Browse more venture capital transactions:
Prev: 5/8/2012: Elemental Technologies venture capital transaction
Next: 5/8/2012: H2scan venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs